P53 Activation of Mesenchymal Stromal Cells Partially Abrogates Microenvironment-mediated Resistance to FLT3 Inhibition in AML Through HIF-1α-mediated Down-regulation of CXCL12

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2011 Aug 27

PMID 21868571

Citations 61

Authors

Kensuke Kojima

Teresa McQueen

Ye Chen

Rodrigo Jacamo

Marina Konopleva

Naoki Shinojima

Elizabeth Shpall

Xuelin Huang

Michael Andreeff

Affiliations

Soon will be listed here.

Abstract

Fms-like tyrosine kinase-3 (FLT3) inhibitors have been used to overcome the dismal prognosis of acute myeloid leukemia (AML) with FLT3 mutations. Clinical results with FLT3 inhibitor monotherapy have shown that bone marrow responses are commonly less pronounced than peripheral blood responses. We investigated the role of p53 in bone marrow stromal cells in stromal cell-mediated resistance to FLT3 inhibition in FLT3 mutant AML. While the FLT3 inhibitor FI-700 induced apoptosis in FLT3 mutant AML cells, apoptosis induction was diminished under stromal coculture conditions. Protection appeared to be mediated, in part, by CXCL12 (SDF-1)/CXCR4 signaling. The protective effect of stromal cells was significantly reduced by pre-exposure to the HDM2 inhibitor Nutlin-3a. p53 activation by Nutlin-3a was not cytotoxic to stromal cells, but reduced CXCL12 mRNA levels and secretion of CXCL12 partially through p53-mediated HIF-1α down-regulation. Results show that p53 activation in stroma cells blunts stroma cell-mediated resistance to FLT3 inhibition, in part through down-regulation of CXCL12. This is the first report of Nutlin effect on the bone marrow environment. We suggest that combinations of HDM2 antagonists and FLT3 inhibitors may be effective in clinical trials targeting mutant FLT3 leukemias.

Citing Articles

Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial.

Dang T, Wickramasinghe N, Jayaraman P, Burbury K, Alexander M, Whitechurch A JMIR Form Res. 2025; 9:e65302.

PMID: 39969972 PMC: 11888109. DOI: 10.2196/65302.

HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects.

Shi Y, Gilkes D Cell Mol Life Sci. 2025; 82(1):44.

PMID: 39825916 PMC: 11741981. DOI: 10.1007/s00018-024-05537-0.

Proteomic and metabolomic exploration in relapse acute myeloid leukemia bone marrow supernatant combined with genetic characteristics.

Ji X, Yang C, Niu C BMC Cancer. 2024; 24(1):1545.

PMID: 39695514 PMC: 11657831. DOI: 10.1186/s12885-024-13286-3.

CXCR4 as a therapeutic target in acute myeloid leukemia.

Korbecki J, Bosiacki M, Kupnicka P, Barczak K, Chlubek D, Baranowska-Bosiacka I Leukemia. 2024; 38(11):2303-2317.

PMID: 39261603 DOI: 10.1038/s41375-024-02326-3.

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.

Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M Cell Commun Signal. 2023; 21(1):252.

PMID: 37735675 PMC: 10512514. DOI: 10.1186/s12964-023-01282-2.

References

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

Whitman S, Ruppert A, Radmacher M, Mrozek K, Paschka P, Langer C . FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2007; 111(3):1552-9. PMC: 2214747. DOI: 10.1182/blood-2007-08-107946. View

Sato T, Yang X, Knapper S, White P, Smith B, Galkin S . FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011; 117(12):3286-93. PMC: 3069670. DOI: 10.1182/blood-2010-01-266742. View

Fukuda S, Broxmeyer H, Pelus L . Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis. Blood. 2004; 105(8):3117-26. DOI: 10.1182/blood-2004-04-1440. View

Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M . p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006; 66(22):10671-6. DOI: 10.1158/0008-5472.CAN-06-2323. View

Kindler T, Lipka D, Fischer T . FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010; 116(24):5089-102. DOI: 10.1182/blood-2010-04-261867. View

El-Deiry W, Kern S, Pietenpol J, Kinzler K, Vogelstein B . Definition of a consensus binding site for p53. Nat Genet. 1992; 1(1):45-9. DOI: 10.1038/ng0492-45. View

Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H . Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood. 2010; 116(1):71-80. PMC: 2904583. DOI: 10.1182/blood-2010-01-261628. View

Dessein A, Stechly L, Jonckheere N, Dumont P, Monte D, Leteurtre E . Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res. 2010; 70(11):4644-54. DOI: 10.1158/0008-5472.CAN-09-3828. View

10.

Tabatabai G, Frank B, Mohle R, Weller M, Wick W . Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain. 2006; 129(Pt 9):2426-35. DOI: 10.1093/brain/awl173. View

11.

Weisberg E, Sattler M, Ray A, Griffin J . Drug resistance in mutant FLT3-positive AML. Oncogene. 2010; 29(37):5120-34. DOI: 10.1038/onc.2010.273. View

12.

Carvalho C, Santos R, Cardoso S, Correia S, Oliveira P, Santos M . Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009; 16(25):3267-85. DOI: 10.2174/092986709788803312. View

13.

Kojima K, Konopleva M, Samudio I, Shikami M, Cabreira-Hansen M, McQueen T . MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005; 106(9):3150-9. PMC: 1895324. DOI: 10.1182/blood-2005-02-0553. View

14.

Weisberg E, Kung A, Wright R, Moreno D, Catley L, Ray A . Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007; 6(7):1951-61. DOI: 10.1158/1535-7163.MCT-06-0810. View

15.

Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T . Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood. 2003; 102(8):2969-75. DOI: 10.1182/blood-2002-12-3813. View

16.

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

17.

Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M . Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis. 2006; 11(3):427-40. DOI: 10.1007/s10495-006-4066-x. View

18.

Kalatskaya I, Berchiche Y, Gravel S, Limberg B, Rosenbaum J, Heveker N . AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009; 75(5):1240-7. DOI: 10.1124/mol.108.053389. View

19.

Fukuda S, Singh P, Moh A, Abe M, Conway E, Boswell H . Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood. 2009; 114(2):394-403. PMC: 2714213. DOI: 10.1182/blood-2008-11-188714. View

20.

Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y . Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia. 2009; 24(1):33-43. DOI: 10.1038/leu.2009.212. View